Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial
- 9 February 2022
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 248, 72-83
Abstract
No abstract availableKeywords
Funding Information
- Medtronic
- National Institutes of Health (U01HL105561)
- National Institutes of Health (U01HL105907)
- National Institutes of Health (U01HL105565)
- National Institutes of Health (U01HL105462)
- National Institutes of Health (UL1 TR002243)
- National Institutes of Health (11UL1 TR001445)
- Omron Healthcare
- National Center for Advancing Translational Sciences
- AstraZeneca
- Amgen
- Arbor Pharmaceuticals
This publication has 27 references indexed in Scilit:
- Causes of late mortality with dual antiplatelet therapy after coronary stentsEuropean Heart Journal, 2015
- 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical TrialsJACC, 2015
- Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting StentsNew England Journal of Medicine, 2014
- Temporal Trends in Ischemic Heart Disease Mortality in 21 World Regions, 1980 to 2010Circulation, 2014
- Cancer risks associated with external radiation from diagnostic imaging proceduresCA: A Cancer Journal for Clinicians, 2012
- The Bypass Angioplasty Revascularization Investigation 2 Diabetes Randomized Trial of Different Treatment Strategies in Type 2 Diabetes Mellitus With Stable Ischemic Heart DiseaseCirculation, 2009
- A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery DiseaseNew England Journal of Medicine, 2009
- Solid Cancer Incidence in Atomic Bomb Survivors: 1958–1998Radiation Research, 2007
- Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000New England Journal of Medicine, 2007
- Optimal Medical Therapy with or without PCI for Stable Coronary DiseaseNew England Journal of Medicine, 2007